Home > Neurology > AAN 2023 > AAN 2023 Highlights Podcast

AAN 2023 Highlights Podcast

Presented by
Robert van den Heuvel, Medicom
AAN 2023

In this episode, Medicom’s correspondent covers 6 presentations from the annual meeting of the American Academy of Neurology (AAN 2023), held in Boston, Massachusetts, from 22-27 April 2023.
The topics discussed are:

  1. Teriflunomide prevents conversion to MS in patients with RIS
    In people with radiologically isolated syndrome, treatment with teriflunomide resulted in a 62% risk reduction compared with a placebo for a first clinical event related to the CNS. These outcomes add evidence for the benefit of early intervention with disease-modifying treatment in the demyelinating spectrum of multiple sclerosis.
  2. First-ever ALS platform trial reports on outcomes of 4 treatments
    The HEALEY ALS Platform trial accelerates the path to new therapies for amyotrophic lateral sclerosis by testing multiple investigational products concurrently and sequentially. Results of 4 regimens which had concluded the RCT period were shared at the AAN 2023 meeting: zilucoplan, verdiperstat, CNM-Au8, and pridopidine.
  3. Atogepant helps prevent treatment-resistant episodic migraine
    In the randomised, double-blind, placebo-controlled ELEVATE trial, atogepant 60 mg once daily was effective in preventing difficult-to-treat episodic migraine in patients who had previously failed between 2 and 4 classes of oral preventive migraine medications. Atogepant was safe and well-tolerated.
  4. Spinal cord stimulation eases painful diabetic neuropathy
    In a randomised controlled trial, 10 kHz spinal cord stimulation provides durable pain relief to patients with painful diabetic neuropathy. The safety of the device was acceptable. Treatment effects at 6 months were maintained at 24 months.
  5. Donanemab shows rapid and deep plaque clearance in early Alzheimer’s disease
    More patients with early symptomatic Alzheimer’s disease (AD) reached amyloid clearance and plaque reductions at 6 months with donanemab than with aducanumab in the TRAILBLAZER-ALZ 4 study. Donanemab’s rapid and deep plaque clearance was associated with improvements in plasma phospho-tau, a key biomarker of AD.
  6. Ravulizumab effective in AQP4+ NMOSD
    In the open-label, phase 3 trial CHAMPION-NMOSD, ravulizumab significantly lowered the risk of relapse and worsening of the Hauser Ambulation Index (HAI) score versus placebo in participants with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD).

Enjoy listening!

Copyright ©2023 Medicom Medical Publishers

Posted on